Palatin
Manufacturing · New Jersey, United States · 11-50 Employees
View Company Info for Free
Overview
Headquarters
103 Carnegie Center Dr Ste 300, Princeto...Phone Number
(609) 495-2200Website
www.palatin.comRevenue
-Stock Symbol
PTNTIndustry
ZI Rank: 1
Signal Type
Dec
Jan
Feb
Mar
Apr
May
ZI Rank
3
2
1
1
1
1
About Palatin
Palatin Technologies, Inc., a biopharmaceutical company, develops targeted, receptor-specific peptide therapeutics for the treatment of various diseases in the United States. The companys principal product is Bremelanotide, an as needed subcutaneous injectable peptide melanocortin receptor agonist, which is in the Phase III clinical studies for the treatment of premenopausal women with hypoactive sexual desire disorder (HSDD). Its drug development programs also include Melanocortin receptor-4 (MC4r) peptides and small molecule agonists that are under the preclinical trials for the treatment of conditions responsive to MC4r activation, including female sexual dysfunction, HSDD, erectile dysfunction, obesity, and diabetes; and Melanocortin receptor-1 peptide agonists, which are under preclinical studies for the treatment of inflammatory and dermatologic disease indications, as well as other Melanocortin receptors. In addition, the company is involved in the development of natriuretic pepRead more
Palatin Org Chart
Sell smarter with deeper company insights.
ZoomInfo gives you access to real-time firmographics, buying signals, org charts, and decision-makers - helping your GTM teams prioritize accounts, personalize outreach with AI-driven automation, and close deals faster.
Is Palatin your ideal customer? 
Let us give you the heads up on whether it's a good time to reach out
Earning: See what the market has to say on Palatin recently announced quarterly report
Funding: Get notified immidiatlly once Palatin has new funding data
Website visits: Recent activity has been detected on your website
Click to see if Palatin had a recent Job posting/layoffs
Congratulate Masked Content for being promoted to Masked Content at Palatin
Check out if Palatin is spiking on competitors!
Competitive Alert! Recent activity has been detected by your competitor Masked Content
Palatin, which may be a good buyer, showed buying intent in Masked Content Topic
Check if Palatin has recently received funding, and reach out quickly before it becomes old news!
Product Launch: Get notified when Palatin launches new products
Recommended Actions
Reach out to Masked Content who joined Palatin as Masked Content
Find 3 more new buyers
Compare Similar Companies to Palatin
Compare insights from companies similar to Palatin, focusing on performance, financial data, growth rates, and unique benchmarks to identify key industry trends and opportunities.
Revenue
Number of Employees
Type
Funding
Founded In
$114.2M
51-200
Public
$462.1M
1994
JB
Jennifer BuellPresident and CEO of MiNK Therapeutics, Chairman, Executive Council At Agenus
Company Profile Activity
Activity Insights
Palatin is experiencing very low activity levels compared to other companies in the Manufacturing sector.
What does this means?
Palatin is drawing exceptional interest within the Manufacturing industry, suggesting notable developments or strong market momentum, learn more about Palatin.
Palatin financials insights
Gather financial insights about Palatin, including details on funding rounds, investors, total funding, and acquisitions, to gain a comprehensive understanding of their financial strategy.
2013
Other Financing Round
$1.8M
2014
Multiple Rounds
$31.9M
2015
Share Placement
$19.8M
Debt
$10M
2016
Share Placement
$9.2M
Share Placement
$16.5M
2023
Other Financing Round
$4.7M
Palatin Tech Stack
A closer look at the technologies used by Palatin
See more technologies
Most Recent Scoops
Earnings
Earnings, Finance
Earnings
Earnings, Finance
Earnings
Earnings, Finance
Earnings
Earnings, Finance
Earnings
Earnings, Finance
Palatin News & Media
Palatin Reports Fiscal Third Quarter 2026 Financial Results and Provides Business Update
Advancing MC4R-based obesity programs for rare obesity disorders with a focus on improved tolerability and long-term use, and key IND submissions targeted in calendar 2026 and 2027 Programs target rare obesity disorders linked to the MC4R pathway, including hypothalamic obesity,...Palatin Reports Second Quarter Fiscal Year 2026 Financial Results and Provides Corporate Update
Advancing differentiated MC4R-based obesity programs into clinical development Melanocortin-based obesity therapies targeting rare MC4R pathway disorders with a primary focus on hypothalamic obesity and Prader-Willi syndrome Oral small-molecule MC4R agonist PL7737 progressing through...Palatin Reports First Quarter Fiscal Year 2026 Financial Results and Provides Corporate Update
Significant progress on multiple fronts – obesity pipeline advancing towards the clinic, out-licensing collaboration, strengthened balance sheet, and reinstatement of NYSE American trading Melanocortin-based therapies for obesity PL7737 IND-enabling toxicology underway; IND submission and...Palatin Technologies Announces Closing of Upsized $18.2 Million Public Offering with the Full Exercise of the Underwriters' Over-Allotment Option
Trading of Palatin's common shares resumed trading on NYSE today, November 12, 2025, under the symbol "PTN" PRINCETON, N.J., Nov. 12, 2025 /PRNewswire/ -- Palatin Technologies, Inc. (NYSE American: PTN) ("Palatin" or the "Company"), a biopharmaceutical company developing first-in-class...
Read more news
Top Manufacturing Companies
Top companies in Australia by revenue
Top companies in New Zealand by revenue
Frequently Asked Questions Regarding Palatin
Sign Up For FreeTo access detailed company insights
Palatin Technologies, Inc., a biopharmaceutical company, develops targeted, receptor-specific peptide therapeutics for the treatment of various diseases in the United States. The companys principal product is Bremelanotide, an as needed subcutaneous injectable peptide melanocortin receptor agonist, which is in the Phase III clinical studies for the... Read More
